TG Therapeutics Inc

NASDAQ:TGTXUnited States

Jun 11, 2024

Show headlines and story abstract

• Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises, from 8:45AM ET on Tuesday Jun 11, 2024 by Dow Jones

  8:45AM ET on Tuesday Jun 11, 2024 by Dow Jones
  Companies Mentioned: LLY, TGTX, RHHBY, TLSA, BIIB
  
  Presentations are available on the Publications page, located within the Pipeline section, of the Company's website at https://www.tgtherapeutics.com/publications/.
  
  ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline.